<DOC>
	<DOCNO>NCT00144599</DOCNO>
	<brief_summary>This double-blind , Phase III study evaluate efficacy , safety PK MRA patient sJIA .</brief_summary>
	<brief_title>Study MRA Systemic Juvenile Idiopathic Arthritis ( sJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Inclusion criterion Patients diagnose systemic JIA base International League Associations Rheumatology criterion ( 1997 ) Patients 2 19 year age Patients 16 year age onset Patients treated corticosteroid ( continue treatment 3 month longer dose â‰¥0.2 mg/kg prednisolone equivalent ) fail respond adequately treatment could continue dose could increase due adverse drug reaction Exclusion criterion Patients treat infliximab etanercept within 12 week treatment investigational product Patients receive follow treatment within 4 week treatment investigational product 1 . Surgical treatment ( e.g. , operation ) 2 . Plasma exchange therapy ''</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>